Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$1.17 USD
-0.03 (-2.50%)
Updated Aug 5, 2024 03:59 PM ET
After-Market: $1.18 +0.01 (0.85%) 6:34 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Nektar Therapeutics [NKTR]
Reports for Purchase
Showing records 81 - 100 ( 397 total )
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
2H20 Updates Could Address Sentiment; Target Lowered to $26
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
From TINA to Cash Is King and Other Musings
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Runners up Is the New Killing It, and Other Tidbits
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Let?s Caucus, or Never Again; In an Otherwise Ho-Hum Earnings Week
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Amended Bempeg Collaboration Reflects the Limitations of a "Not Alpha" IL-2
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
2020 Catalyst Calendar and Top Picks Across Mid, Small, and Micro Caps
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Upward Bias Exiting SITC; Target Increased to $32
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Competitive Landscape Presents Tougher Challenges for Bempeg Post ESMO
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D